Takeda Pharmaceutical Company Limited
TKPHF
$30.58
$0.391.29%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -11.40% | 2.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.40% | 2.48% | |||
| Cost of Revenue | 9.02% | 1.00% | |||
| Gross Profit | -21.75% | 3.24% | |||
| SG&A Expenses | -0.40% | 6.72% | |||
| Depreciation & Amortization | -26.32% | -0.86% | |||
| Other Operating Expenses | -192.36% | 298.41% | |||
| Total Operating Expenses | -11.65% | 7.85% | |||
| Operating Income | -9.27% | -27.32% | |||
| Income Before Tax | -427.91% | 354.68% | |||
| Income Tax Expenses | -377.31% | -27.74% | |||
| Earnings from Continuing Operations | -442.61% | 946.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 36.37% | -24.93% | |||
| Net Income | -442.98% | 940.31% | |||
| EBIT | -9.27% | -27.32% | |||
| EBITDA | 211.33% | -50.77% | |||
| EPS Basic | -442.68% | 940.24% | |||
| Normalized Basic EPS | -39.64% | -15.32% | |||
| EPS Diluted | -448.48% | 926.23% | |||
| Normalized Diluted EPS | -38.63% | -16.71% | |||
| Average Basic Shares Outstanding | 0.08% | 0.08% | |||
| Average Diluted Shares Outstanding | -1.58% | 1.77% | |||
| Dividend Per Share | -- | -100.00% | |||
| Payout Ratio | -1.02% | 2.93% | |||